Philipp S. Lienemann

Philipp S. Lienemann

Auto-generated profile, based on publicly available information

Philipp S. Lienemann

Department of Obstetrics, University Hospital Zürich, Zürich, Switzerland

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Biophysical Journal
Verified
Journal Article
Closed access
MEMartin Ehrbar
Martin Ehrbar
ASA. Sala
A. Sala
PLP. Lienemann
P. Lienemann
ARA. Ranga
A. Ranga
KMK. Mosiewicz
K. Mosiewicz
MLMatthias Lutolf
Matthias Lutolf

13 October 2013 in Nature Materials
Verified
Journal Article
Closed access
KMKatarzyna A. Mosiewicz
Katarzyna A. Mosiewicz
LKLaura Kolb
Laura Kolb
AVAndré J. van der Vlies
André J. van der Vlies
MMMikaël M. Martino
Mikaël M. Martino
PLPhilipp S. Lienemann
Philipp S. Lienemann
MLMatthias P. Lutolf
Matthias P. Lutolf

18 February 2010 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
CGClaudio Guetg
Claudio Guetg
PLPhilipp Lienemann
Philipp Lienemann
VSValentina Sirri
Valentina Sirri
IGIngrid Grummt
Ingrid Grummt
DHDanièle Hernandez‐Verdun
Danièle Hernandez‐Verdun
RSRaffaella Santoro
Raffaella Santoro
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 September 2012 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
PLPhilipp S. Lienemann
Philipp S. Lienemann
MLMatthias P. Lutolf
Matthias P. Lutolf
MEMartin Ehrbar
Martin Ehrbar

1 May 2016 in Biomaterials
Verified
Journal Article
Closed access
FAFraz Anjum
Fraz Anjum
PLPhilipp S. Lienemann
Philipp S. Lienemann
SMStéphanie Metzger
Stéphanie Metzger
JBJeff Biernaskie
Jeff Biernaskie
MKMichael S. Kallos
Michael S. Kallos
MEMartin Ehrbar
Martin Ehrbar

5 February 2020 in Advanced Science
Verified
Journal Article
Open access
PDF file
PLPhilipp S. Lienemann
Philipp S. Lienemann
QVQueralt Vallmajo‐Martin
Queralt Vallmajo‐Martin
PPPanagiota Papageorgiou
Panagiota Papageorgiou
UBUlrich Blache
Ulrich Blache
SMStéphanie Metzger
Stéphanie Metzger
MEMartin Ehrbar
Martin Ehrbar
The treatment of bone defects with recombinant bone morphogenetic protein‐2 (BMP‐2) requires high doses precluding broad clinical application. Here, a bioengineering approach is presented that strongly improves low‐dose BMP‐2‐based bone regeneration by mobilizing healing‐associated mesenchymal progenitor cells (MPCs). Smart synthetic hydrogels are used to trap and study endogenous MPCs trafficking to bone defects. Hydrogel‐trapped and prospectively isolated MPCs differentiate into multiple lineages in vitro and form bone in vivo. In vitro screenings reveal that platelet‐derived growth factor BB (PDGF‐BB) strongly recruits prospective MPCs making it a promising candidate for the engineering of hydrogels that enrich endogenous MPCs in vivo. However, PDGF‐BB inhibits BMP‐2‐mediated osteogenesis both in vitro and in vivo. In contrast, smart two‐way dynamic release hydrogels with fast‐release of PDGF‐BB and sustained delivery of BMP‐2 beneficially promote the healing of bone defects. Collectively, it is shown that modulating the dynamics of endogenous progenitor cells in vivo by smart synthetic hydrogels significantly improves bone healing and holds great potential for other advanced applications in regenerative medicine.